PT2658844T - Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb) - Google Patents

Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)

Info

Publication number
PT2658844T
PT2658844T PT118058494T PT11805849T PT2658844T PT 2658844 T PT2658844 T PT 2658844T PT 118058494 T PT118058494 T PT 118058494T PT 11805849 T PT11805849 T PT 11805849T PT 2658844 T PT2658844 T PT 2658844T
Authority
PT
Portugal
Prior art keywords
pkb
akt
preparation
pharmaceutical use
pyrimidine derivatives
Prior art date
Application number
PT118058494T
Other languages
English (en)
Inventor
Brollo Maurice
Carry Jean-Christophe
Certal Victor
Didier Eric
Doerflinger Gilles
El Ahmad Youssef
Filoche-Romme Bruno
Halley Frank
Andreas Karlsson Karl
Schio Laurent
Thompson Fabienne
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1061298A external-priority patent/FR2969609B1/fr
Priority claimed from FR1061300A external-priority patent/FR2969610B1/fr
Priority claimed from FR1061303A external-priority patent/FR2969607B1/fr
Priority claimed from FR1061297A external-priority patent/FR2969608B1/fr
Priority claimed from FR1061301A external-priority patent/FR2969614A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT2658844T publication Critical patent/PT2658844T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT118058494T 2010-12-28 2011-12-22 Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb) PT2658844T (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR1061298A FR2969609B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de 6-oxo-dihydro-pyrimidine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061300A FR2969610B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061303A FR2969607B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de thiopyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061297A FR2969608B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de (5-halo-6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061301A FR2969614A1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1159315 2011-10-14
FR1159316 2011-10-14
FR1159313 2011-10-14
FR1159317 2011-10-14

Publications (1)

Publication Number Publication Date
PT2658844T true PT2658844T (pt) 2017-01-24

Family

ID=45464546

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118058494T PT2658844T (pt) 2010-12-28 2011-12-22 Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)

Country Status (12)

Country Link
US (1) US9133168B2 (pt)
EP (1) EP2658844B1 (pt)
CY (1) CY1118858T1 (pt)
DK (1) DK2658844T3 (pt)
ES (1) ES2612492T3 (pt)
HR (1) HRP20170119T1 (pt)
HU (1) HUE030393T2 (pt)
LT (1) LT2658844T (pt)
PL (1) PL2658844T3 (pt)
PT (1) PT2658844T (pt)
SI (1) SI2658844T1 (pt)
WO (1) WO2012089633A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819422A (zh) * 2014-03-18 2014-05-28 南通佰华生物医药研究有限公司 一种制备手性n-取代-2-吗啉甲醇类化合物的方法
MX2016016517A (es) 2014-06-13 2017-05-01 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-cinasa.
EA201692266A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
BR112016028819A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
KR20170012557A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN106966951B (zh) * 2017-04-21 2020-01-31 常州佳德医药科技有限公司 4-氟-2-甲基吲哚及其制备方法和应用
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
BR112022022530A2 (pt) 2020-05-05 2023-02-23 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk
CN115707685A (zh) * 2021-08-20 2023-02-21 中国石油化工股份有限公司 一种制备胺-环氧卤丙烷聚合单体的方法及产物和系统

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416884A (en) 1978-04-12 1983-11-22 Otsuka Pharmaceutical Co., Ltd. Piperazinylbenzoheterocyclic compounds
CA2398163C (en) 2000-01-24 2011-02-22 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
WO2004016607A1 (en) 2002-08-16 2004-02-26 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
ES2313019T3 (es) 2003-05-09 2009-03-01 F. Hoffmann-La Roche Ag Metil-indoles y metil-pirrolopiridinas como angonistas adrenergicos de alfa-1.
US20070083053A1 (en) 2003-06-27 2007-04-12 Nissan Chemical Industries, Ltd. Process for producing indole compound
BRPI0511834A (pt) 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
ITMI20060621A1 (it) 2006-03-31 2007-10-01 Dac Srl Nuova classe di inibitori delle istone deacetilasi
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
WO2006126010A2 (en) 2005-05-26 2006-11-30 Kudos Pharmaceuticals Limited Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
CN101309904A (zh) 2005-09-29 2008-11-19 惠氏公司 作为单胺再摄取调节剂用于治疗血管舒缩症状(vasomotorsymptoms,vms)的1-(1h-吲哚-1-基)-3-(甲基氨基)-1-苯基丙-2-醇衍生物和相关化合物
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
WO2008148074A2 (en) 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same
BRPI0814818A2 (pt) 2007-07-09 2019-09-10 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ATE554075T1 (de) 2007-07-09 2012-05-15 Astrazeneca Ab Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
BRPI0814503A2 (pt) 2007-07-09 2017-05-16 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
ES2425183T3 (es) 2007-08-14 2013-10-11 Concert Pharmaceuticals Inc. Derivados de oxazolidinonas sustituidas
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
CN101925588B (zh) 2008-01-25 2014-01-15 先正达参股股份有限公司 用作杀虫剂的2-氰基苯基磺酰胺衍生物
WO2010056631A1 (en) * 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
ES2464125T3 (es) * 2009-07-02 2014-05-30 Sanofi Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT

Also Published As

Publication number Publication date
EP2658844B1 (fr) 2016-10-26
SI2658844T1 (sl) 2017-02-28
LT2658844T (lt) 2017-02-10
US9133168B2 (en) 2015-09-15
US20130274253A1 (en) 2013-10-17
PL2658844T3 (pl) 2017-04-28
DK2658844T3 (en) 2017-02-06
HRP20170119T1 (hr) 2017-03-24
ES2612492T3 (es) 2017-05-17
WO2012089633A1 (fr) 2012-07-05
WO2012089633A9 (fr) 2012-08-23
EP2658844A1 (fr) 2013-11-06
HUE030393T2 (en) 2017-05-29
CY1118858T1 (el) 2018-01-10

Similar Documents

Publication Publication Date Title
LT2658844T (lt) Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
IL266510B (en) History of aminopyrimidines, their preparation and pharmaceutical preparations containing them
IL220863A (en) Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
SI2655375T1 (sl) Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
IL225824A0 (en) History of quinoxaline, their preparation and pharmaceutical preparations containing them
IL222858A0 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
EP2563125A4 (en) AZAINDOLE AS JANUSKINASE HEMMER
IL227406A0 (en) Pyrimidine gyrase and topoisomerase inhibitors and their uses
PL2562172T3 (pl) Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania
SG10201402867TA (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
IL226094A0 (en) The history of pyrazine, their preparation and pharmaceutical preparations containing them
IL232701A (en) Pirazine compounds that inhibit sick kinase, pharmaceutical preparations that contain them and their use in the preparation of drugs
IL227404A0 (en) Pyrimidine history, their preparation and pharmaceutical preparations containing them
ZA201306416B (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2742020A4 (en) N1-CYCLIC AMIN-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
IL233415A0 (en) Imidazopyridine derivatives of tyrosine kinase inhibitors, preparations containing them and their uses
IL225823A0 (en) History of quinazoline, their preparation and pharmaceutical preparations containing them
AP2013006816A0 (en) Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation
IL225378A0 (en) History of phenylquinazoline, their preparation and pharmaceutical preparations containing them
IL226344A (en) History of imidazole, their use in the preparation of pharmaceuticals and pharmaceuticals containing them